DEA Okays Importing Trippy DMT for 'Therapy'—Hallucinations on Official List?
Published Date: 3/7/2025
Notice
Summary
LTS Therapy Systems, LLC wants to become an official importer of a powerful controlled substance called Dimethyltryptamine (DMT), which is a Schedule I drug. This means they’ll handle importing this substance under strict government rules. People and companies involved can share their thoughts or ask for a hearing by April 7, 2025, so keep an eye on that deadline!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Applicant Seeks DMT Importer Registration
LTS Therapy Systems, LLC applied on November 20, 2024 to be registered as an importer of Dimethyltryptamine (DMT), a Schedule I controlled substance (drug code 7435). The company says it plans to import DMT only as bulk active pharmaceutical ingredient (API) for internal research, development, and analytical purposes.
Registration Does Not Allow Commercial Finished Drugs
The notice explicitly states that any authorization will be limited to the registrant's business activity under 21 U.S.C. 952(a)(2) and will not extend to the import of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-03647, Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Baldrige Executive Fellows Program
The National Institute of Standards and Technology is asking for approval to keep collecting info from about 24 applicants yearly for the Baldrige Executive Fellows Program, a cool fellowship that helps professionals grow. They’re giving the public 30 more days to share thoughts before finalizing. This won’t cost much time—just about an hour per person—and it’s totally voluntary for businesses, nonprofits, and individuals interested in applying.
Next: 2025-03649, Proposed Collection; Comment Request; Extension: Rule 17j-1
The SEC wants to keep rules that stop investment fund workers from cheating by trading stocks for themselves unfairly. These rules make sure fund companies have clear ethics codes and check that their employees follow them. If you work at or run these funds, you’ll keep submitting reports and updates, with no new fees or big changes, just an extension of current rules.